Medomics Seeks to Raise up to $4M for Sequencing-Based Mitochondrial Disease Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Personalized medicine startup Medomics said this week that it is in discussions with various undisclosed entities to raise $3 million to $4 million to further develop and market its gene sequencing-based diagnostic test for mitochondrial diseases.

Medomics, based in Azusa, Calif., expects to receive a $1 million investment from an undisclosed corporate co-investor if it can raise $2 million to $3 million in financing from additional investors, Steve Sommer, president and founder of Medomics, told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.